Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity

被引:82
作者
Basavarajappa, Balapal S.
机构
[1] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA
[2] New York State Psychiat Inst & Hosp, Div Analyt Psychopharmacol, New York, NY 10032 USA
[3] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA
关键词
alcoholism; endocannabinoids; CNS; synaptic plasticity; reward; CB1; receptors; alcohol-drinking behavior; therapy;
D O I
10.2174/157015907780866910
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Tile endocannabinoid signaling system is composed of the cannabinoid receptors; their endogenous ligands, the enclocannabinoids; the enzymes that produce and inactivate the endocannabinoids; and die endocannabinoid transporters. The enclocannabinoids are a new family of lipidic signal mediators, which includes amides, esters, and ethers of long-chain polyunsaturated fatty acids. Endocannabinoids signal through the same cell surface receptors that are targeted by Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the active principles of cannabis sativa preparations like hashish and marijuana. The biosynthetic pathways for the synthesis and release of endocannabinoids are still rather uncertain. Unlike neurotransmitter molecules that are typically held in vesicles before synaptic release, enclocannabinoids are synthesized oil demand within the plasma membrane. Once released, they travel in a retrograde direction and transiently suppress presynaptic neurotransmitter release through activation of cannabinoid receptors. The endocannabinoid signaling system is being found to be involved in all increasing number of pathological conditions. In the brain, endocannabinoid signaling is mostly inhibitory and suggests a role for cannabinoids as therapeutic agents in central nervous system (CNS) disease. Their ability to modulate synaptic efficacy has a wide range of functional consequences and provides unique therapeutic possibilities. The present review is focused on new information regarding the endocannabinoid signaling system in the brain. First, the structure, anatomical distribution, and signal transduction mechanisms of cannabinoid receptors are described. Second, the synthetic pathways of enclocannabinoids are discussed, along with the putative mechanisms of their release, uptake, and degradation. Finally, the role of the endocannabinoid signaling system in the CNS and its polential as a therapeutic target in various CNS disease conditions, including alcoholism, are discussed.
引用
收藏
页码:81 / 97
页数:17
相关论文
共 321 条
[111]   Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms [J].
Giuffrida, A ;
Leweke, FM ;
Gerth, CW ;
Schreiber, D ;
Koethe, D ;
Faulhaber, J ;
Klosterkötter, J ;
Piomelli, D .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (11) :2108-2114
[112]   Dopamine activation of endogenous cannabinoid signaling in dorsal striatum [J].
Giuffrida, A ;
Parsons, LH ;
Kerr, TM ;
de Fonseca, FR ;
Navarro, M ;
Piomelli, D .
NATURE NEUROSCIENCE, 1999, 2 (04) :358-363
[113]  
Giuffrida A, 2001, J PHARMACOL EXP THER, V298, P7
[114]   Evidence against the presence of an anandamide transporter [J].
Glaser, ST ;
Abumrad, NA ;
Fatade, F ;
Kaczocha, M ;
Studholme, KM ;
Deutsch, DG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :4269-4274
[115]   Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain [J].
Glass, M ;
Dragunow, M ;
Faull, RLM .
NEUROSCIENCE, 1997, 77 (02) :299-318
[116]   The role of cannabinoids in neurodegenerative diseases [J].
Glass, M .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2001, 25 (04) :743-765
[117]   The pattern of neurodegeneration in Huntington's disease:: A comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease [J].
Glass, M ;
Dragunow, M ;
Faull, RLM .
NEUROSCIENCE, 2000, 97 (03) :505-519
[118]   Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors [J].
Glass, M ;
Van Dellen, A ;
Blakemore, C ;
Hannan, AJ ;
Faull, RLM .
NEUROSCIENCE, 2004, 123 (01) :207-212
[119]   Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a G(s) linkage to the CB1 receptor [J].
Glass, M ;
Felder, CC .
JOURNAL OF NEUROSCIENCE, 1997, 17 (14) :5327-5333
[120]  
GOMEZ DP, 2000, BIOCHEM J, V347, P369